Pfizer lifted full-year revenue and EPS guidance on third-quarter results and detailed regulatory approvals for Talzenna, Tukysa and a positive Elrexfio Phase 3 readout.
The company said its NEK7 degrader lowered multiple inflammatory markers tied to atherosclerosis and plans three Phase 2 trials starting as early as late 2026.
Novartis initiated a Phase 2a/b study of the VAV1-directed molecular glue degrader, triggering a $50 million milestone payment to Monte Rosa under their license agreement.